Close Menu

NEW YORK – Clinical-stage biopharmaceutical company iOnctura SA said on Wednesday that it has dosed the first patient in its Phase I study of its lead investigational agent IOA-244, a highly selective PI3K delta inhibitor.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.